HCC
Oncology · 2008–2025
12decisions
8medicines
5carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nivolumab; ipilimumab First-line treatment of patients with advanced (unresectable) Barcelona Clinic Liver Cancer Stage A, Stage B or Stage C hepatocellular carcinoma. | Jul 2025 | Not recommended | input received Liver Foundation · Pancare Foundation · Rare Cancers Australia |
| durvalumab and tremelimumab First-line treatment of patients with advanced (unresectable) Barcelona Clinic Liver Cancer (BCLC) Stage B or Stage C hepatocellular carcinoma (HCC). | May 2025 | Recommended with restriction | input received Medical Oncology Group · Rare Cancers Australia |
| atezolizumab Subcutaneous injection formulation for multiple cancer indications including locally advanced or metastatic NSCLC, stage IV metastatic NSCLC, extensive-stage… | Mar 2024 | Recommended with restriction | input received Rare Cancers Australia · Lung Foundation Australia |
| atezolizumab Treatment of patients with unresectable locally advanced or metastatic Barcelona Clinic Liver Cancer (BCLC) stage B or stage C hepatocellular carcinoma who… | Jul 2020 | Recommended with restriction | input received Gastroenterological Society · Rare Cancers Australia · Hepatitis Australia · Medical Oncology Group |
| cabozantinib Treatment of advanced hepatocellular carcinoma (HCC) in patients with Barcelona-Clinic Liver Cancer (BCLC) stage B or C disease, WHO performance status ≤1,… | Jul 2019 | Not recommended | none received |
| regorafenib Treatment of patients with unresectable hepatocellular carcinoma (HCC) who have progressed on first-line treatment with a tyrosine kinase inhibitor (TKI). | Jul 2019 | Not recommended | none received |
| lenvatinib First-line treatment of patients with unresectable hepatocellular carcinoma (HCC), Barcelona Clinic Liver Cancer stage B or stage C. | Jul 2018 | Recommended with restriction | input received Medical Oncology Group · Australian Institute |
| regorafenib Treatment of patients with unresectable hepatocellular carcinoma (HCC) who progressed following treatment with sorafenib. | Mar 2018 | Not recommended | none received |
| lenvatinib Advanced (unresectable) Barcelona Clinic Liver Cancer stage B or stage C hepatocellular carcinoma, first-line treatment. | Nov 2018 | Recommended | none received |
| regorafenib Treatment of patients with unresectable hepatocellular carcinoma (HCC) who have progressed following treatment with sorafenib. | Nov 2018 | Not recommended | none received |
| sorafenib advanced hepatocellular carcinoma in patients with unresectable disease | Jul 2008 | Recommended with restriction | no section in document |
| sorafenib tosylate Initial and continuing treatment of advanced hepatocellular carcinoma in patients with unresectable disease, specifically BCLC Stage C HCC with WHO performance… | Jul 2008 | Recommended with restriction | no section in document |
Who spoke
Rare Cancers Australia · Medical Oncology Group · Gastroenterological Society · Hepatitis Australia · Lung Foundation Australia · Australian Institute · Liver Foundation · Pancare Foundation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 10 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.